Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $11.2700 (-1.74%) ($11.2400 - $11.5900) on Tue. Jun. 11, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.81% (three month average) | RSI | 40 | Latest Price | $11.2700(-1.74%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -1.4% a day on average for past five trading days. | Weekly Trend | FOLD declines -1.2% a week on average for past two weeks. | Market Behavior | Normal for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(61%) XBI(57%) IWO(55%) IWM(52%) IWC(50%) | Factors Impacting FOLD price | FOLD will decline at least -1.405% in a week (0% probabilities). VXX(-19%) TLT(-14%) IFRA(-9%) TIP(-1%) UNG(-0%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.405% (StdDev 2.81%) | Hourly BBV | 0 () | Intraday Trend | -2.4% | | | |
|
Resistance Level | $11.89 | 5 Day Moving Average | $11.73(-3.92%) | 10 Day Moving Average | $11.64(-3.18%) | 20 Day Moving Average | $11.89(-5.21%) | To recent high | -21.7% | To recent low | 2.8% | Market Cap | $2.91b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |